May 8, 2021

Featuring perspectives from Drs Joseph Chao and Yelena Y Janjigian on cases from the practice of Dr Daniel Catenacci, including the following topics:

• Introduction (0:00)
• A man in his mid-50s with HER2-negative, microsatellite stable (MSS) metastatic gastroesophageal junction (GEJ) adenocarcinoma with a PD-L1 combined positive score (CPS) of 20 (6:11)
• A man in his mid-50s with MSS localized adenocarcinoma of the esophagus with a PD-L1 CPS of 10 (13:56)
• A man in his late 60s with relapsed HER2-positive, MSS adenocarcinoma of the esophagus with a PD-L1 CPS of 0 (24:59)
• A woman in her mid-30s with relapsed HER2-positive metastatic gastric cancer who experiences rapid disease progression while receiving trastuzumab deruxtecan (46:38)
• A man in his late 60s with newly diagnosed FGFR2b-overexpressing metastatic GEJ adenocarcinoma who receives the investigational agent bemarituzumab in combination with modified FOLFOX6 (51:30)

CME information and select publications